Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.

Michael D Toboni,Sharon Wu,Alex Farrell,Joanne Xiu,Jennifer R Ribeiro,Matthew J Oberley,Rebecca Arend,Britt K Erickson,Thomas J Herzog,Premal H Thaker,Matthew A Powell

Gynecologic oncology（2023）

引用 0|浏览24

暂无评分

摘要

Endometrial cancer patients with MLH1 hypermethylation display significantly decreased survival and discrepant immunotherapy responses compared to patients with MLH1 mutated tumors, which was associated with differential mutational profiles, a more immune cold phenotype, and increased ER/PR expression in MLH1 hypermethylated tumors. Providers may consider early transition from single agent ICI to a multi-agent regimen or hormonal therapy for patients with MLH1 hypermethylated tumors.

查看译文

关键词

Endometrial cancer,MLH1 hypermethylation,MLH1 mutation,Mismatch repair deficiency,Immune microenvironment,Molecular profiling,Precision oncology,Immunotherapy,Hormonal therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要